A kosár üres.

A Szalvesztrolok
könyvben szereplő

KUTATÁSI REFERENCIÁK

 

Attard G, Belldegrun AS, de Bono JS (2005). Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96 (9): 1241-6.

Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd e, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008).Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology 26: 4563.

Attard G, Reid A, A'Hern R, Parker C, Oommen N, Folkerd E, Messiou C, Molife L, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye S, Dearnaley D, Kheoh T, Molina A, and de Bono J (2009). Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer.Journal of Clinical Oncology, 27(23):3742-8.

Barnett JA, UrbauerDL, Murray GI, et al. (2007). Cytochrome P450 1B1 expression in glial cell tu­mors: an immunotherapeutic target.ClinCancer Res.13: 3559-3567.

Bertz RJ, Granneman GR. (1997) Use of in vi­tro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clin Pharmacokinet, 32: 210-58.

Burke, MD. (2009).The silent growth of cancer and its implications for nutritional protection.British Naturopathic Journal, 26:1, 15-18.

Burke, MD, & Potter, G (2006). Salvestrols ... Natural Plant and Cancer Agents?BritishNaturopathic Journal, 23:1,10-13.

Carnell D, Smith R, Daley F, et al. (2004). Target validation of cytochrome P450 CYP1B1 in pros­tate carcinoma with protein expression in associ­ated hyperplastic and premalignant tissue. Int J Radiat Oncol BiolPhys. 58: 500-509.

Chang JT, Chang H, Chen P, et al, (2007). Requirement of aryl hydrocarbon receptor over-expression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res. 13:38-45.

Chang H, Su J, Huang CC, et al. (2005). Using a combination of cytochrome P450 1B1 and b-catenin  for  early  diagnosis   and  prevention  ofcolorectal cancer. Cancer Detect Prevent. 29: 562— 569.

Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH (2003). Cytochrome P450 CYP3A4/5 expression as a Biomarker of Outcome in Osteosarcoma. Journal of Clinical Oncology, 21: 2481-2485.

Dorai T, Aggarwall BB (2004) Role of chemo-protective agents in cancer therapy.Cancer Letters 215: 129-140.

Downie D, McFadyen M, Rooney P, et al. (2005). Profiling cytochrome P450 expression in ovarian cancenidentification of prognostic markers.Clin Cancer Res. 11: 7369-7375.

Everett S, McErlane VM, McLeod K, et al. (2007). Profiling cytochrome P450 CYP1 enzyme expression in primary melanoma and disseminat­ed disease utilizing spectral imaging microscopy (SIM). JClin Oncology. 25: 8556.

Ferrigni, NR, McLaughlin JL (1984). Use of po­tato disc and brine shrimp bioassays to detect ac­tivity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J. Nat. Prod. 47:347-352.

Fuller F (April 26th, 2011). An Orthomolecular Approach    to    Cancer.    4th  Annual    CancerPrevention and Healing Event, Health Action Network Society, Burnaby, B.C., Canada.

Gibson, P. et al., (2003) Cytochrome P450 1B1 (CYP1B1) Is Overexpressed in Human Colon Adenocarcinomas Relative to Normal Colon: Implications for Drug Development.Molecular Cancer Therapeutics, 2: 527-534.

Greer ML, Richman PI, Barber PR, et al, (2004). Cytochrome P450 1B1 (CYP1B1) is expressed during the malignant progression of head and neck squamous cell carcinoma (HNSCC). Proc Amer Cancer Res. 45: Abstract #3701.

Gribben, J.G. et al., (2005) Unexpected associa­tion between induction of immunity to the uni­versal tumor antigen CYP1B1 and response to next therapy.Clinical Cancer Research, 11: 4430-4436.

Haas S, Pierl C, Harth V, etal. (2006). expression of xenobiotic and steroid hormone metaboliz­ing enzymes in human breast carcinomas. Int J Cancer. 119: 1785-1791.

Hanna IH, Dawling S, Roodi N, F. Peter Guengerich FP, Parl FF, (2000). Cytochrome P450 1B1 (CYP1B1) Pharmacogenetics: Association of Polymorphisms with Functional Differences in estrogen Hydroxylation Activity.Cancer Research 60: 3440-3444.

Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, and Thomas R. Sutter TR (1996) 17-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Medical Sciences, 93: 9776-9781.

Hsieh TC, Wu Jm (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Experimental Cell Research 249(1): 109-15. _

Jang M, Cai L, Udeani G, Slowing K, Thomas C, Beecher C, Fong H, Farnsworth N, Kinghorn A, Mehta R, Moon R, Pezzuto J, (1997) Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes.Science 275: 218 - 220.

Jang M, Pezzuto J, (1999) Cancer Chemopreventive Activity of Resveratrol. Drugs Exp Clin Res 25:65-77.

Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR (1998) metabolism of benzo[a]pyrene and benzo[a]pyrene-7, 8-diol by human cytochrome P450 1B1. Carcenogenesis 19: 1847-1853.

Kumarakulasingham M, Rooney PH, Dundas SR, et al. (2005). Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. 11: 3758-3765.

Lin P, Chang H, Ho WL, etal. (2003). Association of aryl hydrocarbon  receptor and  cytochromeP4501B1 expressions in human non-small cell lung cancers.Lung Cancer. 42: 255-261.

Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. (2000). Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 10 : 343-53.

Li NC, & Wakeman M. (October 2009) High-performance liquid chromatography comparison of eight beneficial secondary plant metabolites in the flesh and peel or 15 varieties of apples. The Pharmaceutical Journal, supplement Vol. 283, B40.

LiNC, & Wakeman M. (2009) High-performance liquid chromatography comparison of eight bene­ficial secondary plant metabolites in the flesh and peel or 15 varieties of apples. Journal of Pharmacy and Pharmacology, supplement 1, A132.

Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, and Schultze JL. (2003) The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood.Nov 1;102(9):3287-94.

Magee, J.B., Smith, B.J., and Rimando, A. (2002). Resveratrol Content of Muscadine Berries is Affected by Disease Control Spray Program.Journal of the American Society for Horticultural Science, 37:358-361.

McFadyen MCE, Melvin WT, Murray GI (2004) Cytochrome P450enzymes: Novel op­tions for cancer therapeutics. Molecular Cancer Therapeutics, 3: 363-371.

McFadyen MCE, melvin WT, murray GI (2004) Cytochrome P450CYP1B1 activity in renal cell carcinoma. British Journal of Cancer 91: 966-971.

McFadyen MCE, Cruickshank ME, Miller ID, et al. (2001) CytochromeP450 CYP1B1 over-expression in primary and metastatic ovarian can­cer. British Journal of Cancer 85:242—6.

McFadyen MCE, Breeman S, Payne S, et al. Immunohistochemical localization of cyto­chrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. Journal of Histochemistry and Cytochemistry, 1999; 47:1457-64.

McKay J, Melvin W, Ahsee A, Ewen S, Greenlee W, Marcus C, Burke M, Murray G (1995) expression Of Cytochrome-P450 Cyp1b1 In Breast-CancerFEBS Letters 374(2): 270-272.

Michael M, Doherty MM. (2005) Tumoral Drug Metabolism: Overview and Its Implications for Cancer TherapyJournal of Clinical Oncology, 23, 205-229.

Murray GI, Melvin WT, Greenlee WF, Burke MD, (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1.Annual Review of Pharmacology and Toxicology. 41: 297-316.

Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD, Melvin WT (1997) Tumor specific expression of cytochrome P450 CYP 1B1. Cancer Research, 57: 3026-3031.

Murray GI, McKay JA, Weaver RJ, et al, (1993) Cytochrome P450 expression is a common mo­lecular event in soft tissue sarcomas. Journal of Pathology, 171:49-52,

Oyama, T, Morita, M, Isse, T, et al, (2005). Immunohistochemical evaluation of cytochrome P450 (CYP) and P53 in breast cancer.Front Biosci. 10: 1156-1161.

Patterson LH, Murray GI (2002). Tumour cy­tochrome P450 and drug activation. Current Pharmaceutical Design, 8:1335-1347. _

Port J, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt P, Kopelovich L, Marcus C, Altorki N, Subbaramaiah K, Dannenberg A (2004). Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis, 25(11): 2275-2281.

Potter GA, Burke DM (2006) Salvestrols -Natural Products with Tumour Selective Activity. Journal of Orthomolecular Medicine, 21, 1: 34-36.

Potter GA (2002) The role of CYP 1B1 as a tu­mour suppressor enzyme. British Journal of Cancer, 86 (Suppl 1),S12, 2002.

Potter GA, Patterson LH, Wanogho E et al (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatonnal by the cytochrome P450 enzyme CYP 1B1. British Journal of Cancer, 86: 774-778.

Potter GA, Patterson LH, Burke MD (2001) Aromatic hydroxylation activated (AHA) pro­drugs. US Patent 6,214,886.

Prud'homme A, (2009) Comparative Analysis of Polyphenolic Residues from Grape Pomace to Contain Wine. Training report, Département Chimie, Université du Maine.

Report Of The Independent Vitamin Safety Review Panel. (May 23, 2006). Orthomolecular Medicine News Service.

Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. (2001) Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?Pharmacology and Experimental Therapeutics 296, 537-541.

Rodriguez-Melendez R, Griffin JB & Zempleni J (2004) Biotin Supplementation Increases expression of the Cytochrome P4501B1 Gene in Jurkat Cells, Increasing the Occurrence of Single-Stranded DNA Breaks. The Journal of Nutrition, 134:2222-2228.

Schaefer BA, Dooner C, Burke DM, Potter GA, (2010) Nutrition and Cancer: Further Case Studies Involving Salvestrol. Journal of Orthomolecular Medicine, 25, 1: 17-23.

Schaefer, B.A. (April 2010) Early Cancer Detection. Proceedings of the 39thOrthomolecular Medicine Today Conference, Vancouver, B.C.

Schaefer BA, Hoon LT, Burke DM, Potter GA, (2007) Nutrition and Cancer: Salvestrol Case Studies. Journal of Orthomolecular Medicine, 22, 4: 1-6.

Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Research 56: 2979-2984.

Skov T, Lynge e, Maarup B, Olsen J, Rorth M, Winthereik H [1990].Risk for physicians han­dling antineoplastic drugs [letter to the editor]. The Lancet 336:1446.

Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E [1992]. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 49:855-861.

Sorsa M, Hemminki K, et al. (1985). Occupational exposure to anticancer drugs--potential and real hazards. Mutation Research 154:135-149.

Stellman JM, Zoloth, SR (1986) Cancer chemo-therapeutic agents as occupational hazards: A lit­erature review. Cancer Investigation 4:2, 127-135.

Su, J, Lin, P, Wang, C, etal, (2009). Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res. 29: 509-515.

Surh YJ, Hurh YJ, Kang JY (1999) Resveratrol, an antioxidant in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Letters, June 1: 140(1-2): 1-10.

Tan, H. August/September (2007). Can Food Really be Your Medicine? Townsend Letter, 116-119.

Tan HL, K. Beresford K, Butler PC, Potter GA, & Burke MD, (2007). Salvestrols - Natural Anticancer Prodrugs in The Diet. J. Pharm. Pharmacol. 59: S158

Tan, HL, Butler PC, Burke MD, & Potter GA, (2007). Salvestrols: A New Perspective in NutritionalResearch.Journal of Orthomolecular Medicine, 2007;22(1): 39-47.

Tokizane,  T.  et  al.,   (2005)  Cytochrome  P450CYP1B1 is overexpressed and regulated by hypo-methylation in prostate cancer. Clinical Cancer Research, 11: 5793-5801.

Ware WR, (2009) Nutrition and the Prevention and Treatment of Cancer: Association of Cytochrome P450 CYP1B1 With the Role of Fruit and Fruit Extracts. Integrative Cancer Therapies, 8, 1: 22-28.

Ware WR, (2009) P450 CYP1B1 mediated fluo­rescent tumor markers: A potentially useful ap­proach for photodynamic therapy, diagnosis and establishing surgical margins. Medical Hypotheses, 72: 67-70.

Zhao Z, Kosinska W, Khmelnitsky M, Cavalieri EL, Rogan EG, Chakravarti D, Sacks PG, Guttenplan JB, (2006). Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spec­trum of 4-hydroxyestradiol. Chemical Research in Toxicology, 19: 475-479.

TOVÁBBI  INFORMÁCÓK:

Health Action Network Society#202 — 5262 Rumble Street Burnaby, B.C., V5J 2B6 CANADA
www.hans.org

International Society for Orthomolecular Medicine 16 Florence Avenue Toronto Ontario M2N 1E9 CANADA
www.orthomed.org

Canadian Association of  Holistic Nutrition Professionals CAHN-Pro 150 Consumers Road Toronto, Ontario M2J 1P9
www.cahnpro.org


"... A termékek jelölése, megjelenítése és hirdetése nem állíthatja, vagy sugallhatja, hogy az étrend-kiegészíto betegségek megelozésére, kezelésére alkalmas, vagy ilyen tulajdonsága van."
(forrás:OÉTI)